The data presented in this study demonstrate decreased levels of LAMP1 in the basal ganglia of G2019S mutation carriers compared to iPD and control cases, and are consistent with a model of impairment of lysosomal targeting in LRRK2 PD. Here, LRRK2 is linked to Parkinson disease.